Previous Close | 16.19 |
Open | 16.28 |
Bid | 15.10 x 900 |
Ask | 16.80 x 800 |
Day's Range | 16.04 - 16.80 |
52 Week Range | 14.58 - 60.94 |
Volume | |
Avg. Volume | 348,051 |
Market Cap | 619.721M |
Beta (5Y Monthly) | 1.60 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.80 |
Earnings Date | Aug 03, 2022 - Aug 08, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 39.50 |
Subscribe to Yahoo Finance Plus to view Fair Value for QTRX
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
BILLERICA, Mass., June 09, 2022--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chief Executive Officer, Masoud Toloue, will join the Goldman Sachs 43rd Annual Global Healthcare Conference for a fireside chat on June 16, 2022 at 8:40 a.m., EST.
BILLERICA, Mass., June 06, 2022--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that Karen A. Flynn, Senior Vice President and Chief Commercial Officer of Catalent Pharma Solutions (NYSE: CTLT), has been appointed to Quanterix’ Board of Directors effective June 6, 2022.